Alfuzosin Hydrochloride interactions

Food & lifestyle

• alcohol

  Moderate

  Synergy

  The concurrent use of ethanol and alpha-1 adrenergic blockers may cause increased hypotensive effects. Patients with aldehyde dehydrogenase deficiencies (primarily Asians) may be at a higher risk of this interaction.

  What to do: Patients who develop a flushing reaction after ethanol ingestion (indicates a possible aldehyde dehydrogenase deficiency) should be advised to avoid ethanol or limit their intake. All patients should be warned about the possibility of orthostatic hypotension with concurrent ethanol use.

  2 sources

  1. Kawano Y, Abe H, Kojima S, Takishita S, Omae T "Interaction of alcohol and an a1-blocker on ambulatory blood pressure in patients with essential hypertension." Am J Hypertens 13 (2000): 307-12
  2. "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc (2002):

• food

  Moderate

  Absorption

  Administration of alfuzosin with food enhances oral bioavailability. According to the manufacturer, extent of absorption is 50% higher when administered under fed conditions compared to fasting conditions.

  What to do: To ensure maximal oral absorption, alfuzosin should be administered with or immediately after a meal.

  1 source

  1. "Product Information. Uroxatral (alfuzosin)." sanofi-aventis (2003):

Conditions

Conditions in which Alfuzosin Hydrochloride needs care, as documented in this source.

• Hepatic Insufficiency

  Major

  Alfuzosin is contraindicated for use in patients with moderate or severe hepatic impairment (Child Pugh B and C). The pharmacokinetics of alfuzosin have not been studied in patients with mild hepatic impairment and caution should be exercised if it is administered to such patients.

  1 source

  1. "Product Information. Uroxatral (alfuzosin)." sanofi-aventis (2003):

• Cataract

  Moderate

  Intraoperative Floppy Iris Syndrome has been observed during cataract surgery in some patients on or previously treated with antiadrenergic agents. If a patient is undergoing cataract surgery, the ophthalmologist should be prepared for possible modifications of the surgical technique (iris hooks, iris dilator rings). There does not appear to be a benefit in stopping antiadrenergic agents therapy prior to the cataracts surgery.

  2 sources

  1. "Product Information. Uroxatral (alfuzosin)." sanofi-aventis (2003):
  2. "Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals (2008):

• Hypotension

  Moderate

  Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations. Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose. However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days. Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects. Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes. Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs. Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling. During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur. Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized. If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.

  16 sources

  1. Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974): 171-4
  2. Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982): 455
  3. Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984): 219-28
  4. Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976): 1293-4
  5. "Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977): 1-2
  6. Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977): 429-33
  7. "Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals (2001):
  8. "Product Information. Hytrin (terazosin)." Abbott Pharmaceutical (2001):

  Show all 16 sourcesShow fewer sources

  9. Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994): 22-31
  10. Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994): 1067-74
  11. Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995): 11-8
  12. Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill (1995):
  13. Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996): 406-15
  14. "Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim (2001):
  15. "Product Information. Uroxatral (alfuzosin)." sanofi-aventis (2003):
  16. "Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals (2008):

• Kidney Diseases

  Moderate

  Caution should be exercised when alfuzosin is administered in patients with severe renal impairment as safety data is limited on these patients (CrCl < 30 mL/min).

  1 source

  1. "Product Information. Uroxatral (alfuzosin)." sanofi-aventis (2003):

• Long QT Syndrome

  Moderate

  Alfuzosin should be used with caution in patients with acquired or congenital QT prolongation, or who are taking medications that prolong the QT interval.

  1 source

  1. "Product Information. Uroxatral (alfuzosin)." sanofi-aventis (2003):

Therapeutic duplication

Drug classes that overlap with Alfuzosin Hydrochloride, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.

• alpha-adrenoreceptor antagonists

  The recommended maximum number of medicines in the 'alpha-adrenoreceptor antagonists' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'alpha-adrenoreceptor antagonists' category.

  Example product in the source data (US market): Jalyn